COMMUNIQUÉS West-GlobeNewswire

Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
24/02/2026
LEXINGTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to [...]
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference
24/02/2026
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results
24/02/2026
SUNNYVALE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
Cannabix Technologies Closes Non-Brokered Private Placement
24/02/2026
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (the “Company” or “ [...]
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
24/02/2026
$154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectively BridgeBio reported three [...]
Palvella Therapeutics Announces Proposed Public Offering
24/02/2026
WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat [...]
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
24/02/2026
Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety, Tolerability and [...]
Research in carrot and cherry crops to strengthen local food security
24/02/2026
VANCOUVER, British Columbia, Feb. 24, 2026 (GLOBE NEWSWIRE) -- As climate change continues to disrupt Canada’s agricultural stability, Genome British Columbia (Genome BC) is funding two research collaborations to [...]
AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS
24/02/2026
PRESS RELEASE AB SCIENCE ANNOUNCES THE IDENTIFICATION OF A PLASMA BIOMARKER THAT INDICATES THE ACTIVITY OF MASITINIB IN TREATING AMYOTROPHIC LATERAL SCLEROSIS, AND THAT IS CAPABLE OF IDENTIFYING PATIENTS WITH PRO [...]
Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board
24/02/2026
CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. [...]
Linnaeus Therapeutics Awarded Up to $22 Million from ARPA-H to Advance LNS8801 for Healthspan Preservation
24/02/2026
ARPA-H PROSPR program to support accelerated development of LNS8801 to promote healthy aging HADDONFIELD, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Linnaeus Therapeutics, Inc., a privately held company focused on the [...]
Empathy in Medicine Initiative Announces Student Chapter Program to Empower High School and College Students in Healthcare Leadership
24/02/2026
EMI launches Student Chapter Program to support students in starting empathy-focused healthcare clubs and community projects Empathy in Medicine Initiative (EMI) Image NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- The [...]
Surgery Partners, Inc. Announces Fourth Quarter 2025 Earnings Release Date and Conference Call Details
24/02/2026
BRENTWOOD, Tenn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will [...]
AB Science annonce l'identification d'un biomarqueur plasmatique marqueur de l'activité du masitinib dans le traitement de la SLA
24/02/2026
COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE L'IDENTIFICATION D'UN BIOMARQUEUR PLASMATIQUE MARQUEUR DE L'ACTIVITÉ DU MASITINIB DANS LE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE, ET CAPABLE D'IDENTIFIER LES PATIENTS [...]
Validic Adds Epic Toolbox, Generative AI, Multi-Instance Support, and More to Existing Epic Integration
24/02/2026
New Epic-integrated features including Toolbox alignment, multi-instance support, AI-powered RPM summarization, and expanded wearable integrations help health systems ensure timely, risk-reducing care LOS ANGELES, Feb. [...]
Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments
24/02/2026
Max Homa shares his journey with seborrheic dermatitis to encourage others to take control of their symptoms ZORYVE ® (roflumilast) foam 0.3% is a once-daily, steroid-free, leave-in topical foam uniquely formulated to [...]
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
24/02/2026
Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared to placebo [...]
Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference
24/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its [...]
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
24/02/2026
Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study demonstrating [...]

Pages